Atlas: how CJC-1295 and Ipamorelin restore your GH pulse
Growth hormone is not about more. It is about when.
// tl;dr
CJC-1295 and Ipamorelin push growth-hormone release through two different receptors at once. Higher peak than either alone, with the natural overnight pulse rhythm preserved.
There is a common misconception that growth hormone therapy is about flooding the body with GH. The literature disagrees. What actually matters - for body composition, sleep quality, and tissue repair - is restoring the natural pulse architecture that declines with age. That is what CJC-1295 and Ipamorelin do, together, in a way neither does alone.
The GH pulse, briefly#
Growth hormone is not secreted continuously. It is released in pulses - roughly every 3-4 hours during the day, with the largest pulse coming about an hour after sleep onset, during slow-wave sleep. Total daily GH output declines about 14% per decade after age 30, but pulse frequency and amplitude decline even faster.
Why pulsatility matters: target tissues - muscle, bone, liver - respond differently to pulsed GH than to continuous exposure. Continuous GH causes receptor downregulation and can worsen insulin sensitivity. Pulsatile GH preserves both.
CJC-1295 (no DAC): the GHRH analog#
CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH), the upstream signal that tells the pituitary to release GH. The unmodified form has a half-life of about 7 minutes - too short to be practical. The modified version has a half-life of around 30 minutes.
Critical distinction: CJC-1295 comes in two forms - with DAC and without DAC. The DAC variant binds to albumin, extending the half-life to several days. That sounds desirable until you realize it destroys pulsatility entirely. Continuous GHRH signaling is the opposite of what we want.
Atlas uses no-DAC. The 30-minute half-life aligns with the body's natural pulse architecture instead of overriding it.
Ipamorelin: clean GH secretagogue#
While CJC-1295 mimics the upstream GHRH signal, Ipamorelin works on a different receptor - the growth hormone secretagogue receptor (GHS-R), the same one ghrelin uses. It triggers GH release through a parallel pathway.
What makes Ipamorelin notable is its selectivity. Earlier GHS-R agonists like GHRP-6 or GHRP-2 also stimulate cortisol, prolactin, and appetite - all unwanted side effects. Ipamorelin does not. It releases GH cleanly, without the hormonal noise.
Why combine them#
GHRH analogs (like CJC-1295) and GHS-R agonists (like Ipamorelin) act on different receptors and trigger GH release through distinct pathways. When given together, they produce a synergistic release - significantly larger than either alone - because they are not competing for the same mechanism.
Critically, this synergy preserves pulsatility. The pulse is larger, but it is still a pulse. The receptors get a signal and then a refractory period.
Timing#
- Pre-sleep on an empty stomach. Food blunts the GH response.
- Subcutaneous injection - the typical route in research protocols.
- Cycled to preserve receptor sensitivity.
// the takeaway
Atlas is not trying to make you a teenager again. It is trying to restore the pulse architecture that gives your body its native recovery and tissue-repair signaling. The combination of CJC-1295 (no DAC) and Ipamorelin is the cleanest way the research suggests this can be done.
// selected research
click to expand
The foundational human CJC-1295 study. It used the long-acting DAC variant, demonstrating the multi-day continuous IGF-I elevation that Atlas deliberately avoids by formulating with no-DAC.
open on pubmed· PMID 16352683The paper that introduced Ipamorelin and established its defining trait: GH release without the cortisol and prolactin elevation seen with earlier secretagogues.
open on pubmed· PMID 9849822
// for research purposes. nothing in this article is medical advice.